Is Idorsia Ltd (IDRSF) a Buy, Sell, or Hold?
OTC : IDRSF
Idorsia Ltd
$7.6 USD
$0 (0.0%)
- Volume
- 250
- Average Volume
- 2.68K
- Market Capitalization
- $1.94B
- P/E Ratio
- -6.52
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $8.00
- Year Low
- $3.30
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.60
Company Overview
OTC
Jean-Paul Clozel
Biotechnology
Healthcare
IDRSF
1100
CH
USD
Liquidity Metrics
-1.12
1.60
1.08
0.63
0.00
Sales & Valuation
$221.11M
7.40
-1.32
-11.56
-0.56
Profitability
-$0.52
-$112.05M
-100.74%
-98.24%
19.23%
-45.95%
P/E Metrics
-6.52
0.05
0.05
Analyst Price Target & Rating
0/5
2 Analysts
%
Financial Health Scores
-10.24
3/9
$89.86M
$480.46M
$1.66B
-$160.51M
Key Metrics (TTM)
$2.55B
11.63
-17.75
1.60
19.23%
-59.30%
-14.17%
-10.60%
745 days
Company Executives
| Name | Title |
|---|---|
| Julien Gander | Executive Vice President, Chief Legal & Corporate Development Officer and Company Secretary |
| André C. Muller | Advisor & Director |
| Olivier Lambert | Senior Vice President & Head of Technical Operations |
| Gaby Scherer | Senior Vice President & Head of Global Human Resources |
| Amel Djedour | Senior Vice President & Head of Technical Operations |
| Andrew Jones | Senior Vice President, Head of Corporate Communications & Investor Relations |
| Benjamin Limal | President of Europe & International Markets Region |
| Shalom Jacobovitz | President of Idorsia US |
| Arno Groenewoud | Executive Vice President & Chief Financial Officer |
| Amer Joseph | Executive VP, Chief Medical Officer & Head of Global Clinical Development |
| Martine Clozel | Executive Vice President, Chief Scientific Officer & Head of Research |
| Jean-Paul Clozel | Chairman of the Board & Interim CEO |
Poll Results
No votes yet today — be the first to share your view!
About Idorsia Ltd (OTC:IDRSF) Stock
Established in 2017 and based in Allschwil, Switzerland, Idorsia Ltd operates as a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs. The company's diverse clinical development pipeline targets various therapeutic areas, including central nervous system (CNS), cardiovascular, and immunological disorders, alongside treatments for rare (orphan) diseases. Idorsia maintains a portfolio of strategic alliances: a joint development and commercialization agreement with Janssen Biotech Inc. for aprocitentan and its related products; a licensing deal with Mochida Pharmaceutical for the supply, co-development, and co-marketing of daridorexant; and a collaboration with Hoffman-La Roche Inc. to advance and m ... arket cancer immunotherapy compounds. Additionally, Idorsia is partnering with Antares Pharma, Inc. to create a self-administered drug device product for Selatogrel, and with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is currently undergoing Phase II clinical trials for epilepsy.
Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon
2026-06-09 01:00:00
Ad hoc announcement pursuant to Art. 53 LR Senior secured term loan of up to CHF 250 million with a 5‑year maturity at a fixed 7% interest rate First tranche will fully refinance the existing New Money Facility, maturing in May 2027 Eliminates near‑term debt maturities and strengthens balance sheet and liquidity profile Additional tranches available to fund targeted initiatives accelerating growth and long‑term value creation Allschwil, Switzerland – June 9, 2026 Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, today announced that it has entered into a senior secured term loan agreement of up to CHF 250 million with investment funds managed by Pharmakon Advisors, LP.
2026-06-01 01:05:00
Allschwil, Switzerland – June 1, 2026 Idorsia Ltd (SIX: IDIA) today announced additional positive clinical results for IDOR-1134-2831, its vaccine targeting Clostridioides difficile (C. difficile) in a Phase 1 clinical pharmacology trial. The glycan target of this vaccine is present on both bacteria and spores – the transmissible form of the pathogen responsible for spreading infection – of the most clinically relevant C. difficile strains, including hypervirulent variants. Following initial results in June 2025, which provided the first clinical validation for Idorsia's synthetic glycan vaccine technology, the company advanced the program with a higher-dose cohort.
2026-06-01 01:00:00
Allschwil, Switzerland – June 01, 2026 Idorsia Ltd (SIX: IDIA) announces new analyses from the Phase 3 PRECISION study demonstrating that aprocitentan, Idorsia's dual endothelin receptor antagonist, significantly reduces albuminuria and improves albuminuria risk categories in patients with resistant hypertension. The data were presented by Prof. Markus Schlaich at the 35th Congress of the European Society of Hypertension (ESH).
Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2026
2026-05-06 10:44:00
Allschwil, Switzerland – May 6, 2026 At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Board of Directors.
Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year
2026-04-28 01:00:00
Ad hoc announcement pursuant to Art. 53 LR Preparation is underway to publish the strong pediatric daridorexant data and engage with regulatory authorities on next steps Co-promotion of QUVIVIQ is being expanded across additional European markets to further accelerate growth Partnering discussions for TRYVIO™/JERAYGO™ are ongoing with several parties Allschwil, Switzerland – April 28, 2026 Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, today announced its financial results for the first quarter of 2026.
Frequently Asked Questions
-
What is the current Idorsia Ltd (IDRSF) stock price?
-
Idorsia Ltd(OTC:IDRSF) stock price is $7.6 in the last trading session. During the trading session, IDRSF stock reached the peak price of $8 while $3.3 was the lowest point it dropped to. The percentage change in IDRSF stock occurred in the recent session was 0.0% while the dollar amount for the price change in IDRSF stock was $0.
-
IDRSF's industry and sector of operation?
-
The OTC listed IDRSF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IDRSF?
-
Julien Gander | Executive Vice President, Chief Legal & Corporate Development Officer and Company Secretary
André C. Muller | Advisor & Director
Olivier Lambert | Senior Vice President & Head of Technical Operations
Gaby Scherer | Senior Vice President & Head of Global Human Resources
Amel Djedour | Senior Vice President & Head of Technical Operations -
How many employees does IDRSF have?
-
Number of IDRSF employees currently stands at 1100. IDRSF operates from Hegenheimermattweg 91, Allschwil, BL 4123, CH.
-
Link for IDRSF official website?
-
Official Website of IDRSF is: https://www.idorsia.com
-
How do I contact IDRSF?
-
IDRSF could be contacted at phone #41 58 844 10 10 and can also be accessed through its website. IDRSF operates from Hegenheimermattweg 91, Allschwil, BL 4123, CH.
-
How many shares of IDRSF are traded daily?
-
The average number of IDRSF shares traded daily for last 3 months was 2.68K.
-
What is the market cap of IDRSF currently?
-
The market value of IDRSF currently stands at $1.94B with its latest stock price at $7.6